Results 81 to 90 of about 3,437 (189)

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST

, 2007
In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations.
M. Battegay, M. Kraft, J. P. Sabo, R. T. Steigbigel, S. Rusconi, D. Neubacher, M. Opravil, F. Raffi, G. Blick   +8 more
core   +1 more source

Genotype and phenotype patterns of human immunodeficiency virus type 1 to enfuvirtide during long-term treatments

, 2004
The human immunodeficiency virus type 1 (HIV-1) fusion inhibitor enfuvirtide has recently been introduced into clinical practice and has exhibited efficient anti-HIV-1 activity in combination with other antiretroviral agents.
Danise A, Bagnarelli P, CASTAGNA, ANTONELLA, Hasson H, Carini E, Monachetti A, Lazzarin A, Menzo S, CLEMENTI , MASSIMO   +8 more
core   +1 more source

Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity

, 2010
Enfuvirtide (also known as Fuzeon, T-20, or DP-178) is an antiretroviral fusion inhibitor which prevents human immunodeficiency virus type 1 (HIV-1) from entering host cells.
Mazinghien, Romain, Vincent, Loic, Romain Mazinghien, Gauchet, Cecile, Schols, Dominique, Heidi Bompais, Jérôme Lemoine, Huet, Thierry, Kerbarh, Olivier, Clayette, Pascal, Arnaud Salvador, Querolle, Olivier, Petitou, Maurice, Cécile Gauchet, Jan Balzarini, Bompais, Heidi, Thierry Huet, Olivier Querolle, Loïc Vincent, Maurice Petitou, Olivier Kerbarh, Dubreucq, Guy, Bruno Lucidi, Dominique Schols, Lucidi, Bruno, Balzarini, Jan, Pascal Clayette, Guy Dubreucq, Salvador, Arnaud, Lemoine, Jerome   +29 more
core   +1 more source

Viral susceptibility to aplaviroc and enfuvirtide in virus from participants with resistance to maraviroc.

, 2018
Viral susceptibility to aplaviroc and enfuvirtide in virus from participants with resistance to maraviroc.
Charles Craig (52348), Wei Huang (36889), Mike Westby (2238055), Paul Simpson (528063), David L. Robertson (64202), Marilyn Lewis (199665), Jonathan Toma (6157130), Mike Mosley (6157133), Julie Mori (3389570), Roy Mansfield (6157136), Elna van der Ryst (6157139), Jeannette M. Whitcomb (161996)   +11 more
core   +1 more source

AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus. [PDF]

, 2011
Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral
Semvua Hadija H, Kibiki, Gibson S, Hadija H Semvua, Gibson S Kibiki, Semvua, Hadija H, Kibiki Gibson S   +5 more
core   +1 more source

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy

Biologics: Targets & Therapy, 2008
R Bucciardini1, M Massella1, A Corpolongo2, P Narciso2, V Fragola1, M Mirra1, S Donnini1, O Viganò3, S Costarelli4, V Tozzi21Istituto Superiore di Sanità, Rome, Italy; 2IRCCS L. Spallanzani, Rome, Italy; 3Ospedale L.
R Bucciardini, M Massella, A Corpolongo, P Narciso, V Fragola, et al   +5 more
doaj  

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

Molecules, 2017
Peptides derived from the C-terminal heptad repeat (CHR) of human immunodeficiency virus type 1 (HIV-1) envelope protein transmembrane subunit gp41, such as T20 (enfuvirtide), can bind to the N-terminal heptad repeat (NHR) of gp41 and block six-helix ...
Shan Su, Zhenxuan Ma, Chen Hua, Weihua Li, Lu Lu, Shibo Jiang   +5 more
doaj   +1 more source

Enfuvirtide administration in HIV-positive transgender patients with soft tissue augmentation: US evaluation.

, 2010
Enfuvirtide is a large protein that should be injected subcutaneously to ensure an appropriate absorption. Here we report the case of a transgender HIV-positive patient receiving enfuvirtide with an individualized background regimen of antiretroviral ...
Gervasoni C., FERRAIOLI, GIOVANNA, Ferraris L, Galli M, FILICE, CARLO, Gabrielli E, Riva A   +6 more
core  

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

, 2003
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor.
Delehanty, John, Walmsley, Sharon, Eron Jr., Joseph J., Salgo, Miklos, Drobnes, Claude, Piliero, Peter J., Kuritzkes, Daniel R., Donatacci, Lucille, Chung, Jain, Montaner, Julio S.G., DeMasi, Ralph, Trottier, Benoit, Cohen, Calvin, Henry, Keith, Lalezari, Jacob P., O'Hearn, Mary   +15 more
core   +1 more source

Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation : US evaluation

, 2010
Enfuvirtide is a large protein that should be injected subcutaneously to ensure an appropriate absorption. Here we report the case of a transgender HIV-positive patient receiving enfuvirtide with an individualized background regimen of antiretroviral ...
L. Ferraris, G. Ferraioli, C. Filice, C. Gervasoni, A. Riva, M. Galli, E.M. Gabrielli   +6 more
core